Introduction

 

Scientifically powered and market driven

Formed in late 2015, Synthase Biotech is a New Zealand-owned and located biotechnology early stage company commercialising a proprietary plant enzyme discovered in the USA and being commercialised in the USA.

Our enzyme is Allene Oxide Synthase, a Cytochrome P450, that we have trademarked as Aloxsyn™. Aloxsyn™ neutralises toxic lipid peroxides (LPOs) formed by uncontrolled oxidation of lipids in cell membranes. It operates outside of cells, requires no co-factors to operate and catalyses over 2,500 reactions per second. It is extremely potent and highly stable. Aloxsyn™ is effective in mammals and has been assessed in a regulatory-approved animal testing model where very high doses were well-tolerated by rats.

LPOs cause immense damage if not controlled and are typically at the heart of inflammatory responses. Our enzyme can be applied widely. We have begun commercialisation in cattle artificial insemination and embryo transfer. Forthcoming targets will include pig artificial insemination and initial human applications potentially in tissue and organ storage, and possibly also human fertility. The ultimate target will be a human drug.

We produce Aloxsyn™ recombinantly in our own facilities on Ruakura research campus in Hamilton, NZ and purify and formulate it there too. We employ a highly skilled research, development and manufacturing team that has access within the company and around it to world class equipment and research entities, including a binding relationship with the internationally-respected enzyme faculty at the University of Waikato.